H-rev107 regulates prostaglandin D2 synthase-mediated suppression of cellular invasion in testicular cancer cells

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Shyu, Rong Yaun ^a,b   Wu, Chang Chieh ^c   Wang, Chun Hua ^a   Tsai, Tzung Chieh ^d   Wang, Lu Kai ^e   Chen, Mao Liang ^a   Jiang, Shun Yuan ^a   Tsai, Fu Ming ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

HREV107 type II tumor suppressor; Human H REV107; Murine H rev107; Prostaglandin D2 synthase; Retinoid inducible gene 1; Testis

Indexed keywords

CYCLIC AMP; PROSTAGLANDIN D2; TRANSCRIPTION FACTOR SOX9; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; ISOMERASE; LIPOCALIN; PLA2G16 PROTEIN, MOUSE; PROSTAGLANDIN R2 D-ISOMERASE; PROSTAGLANDIN R2 D ISOMERASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; EXPRESSION VECTOR; GENE EXPRESSION; GENE LOCATION; GENE SILENCING; GENETIC TRANSFECTION; H REV107 GENE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; TESTIS CANCER; TUMOR SUPPRESSOR GENE; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; SERTOLI CELL; SIGNAL TRANSDUCTION; TESTIS TUMOR; TUMOR CELL CULTURE; TUMOR INVASION;

MURINAE;

ANIMALS; CELL DIFFERENTIATION; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PHOSPHOLIPASES A2, CALCIUM-INDEPENDENT; PROSTAGLANDIN D2; SERTOLI CELLS; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84877869040     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-30     Document Type: Article

References (50)

1. Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R, Oncogene 1998 17 1305 1312 10.1038/sj.onc.1202060 9771974 (Pubitemid 28446171)
2. Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells. Nazarenko I, Schafer R, Sers C, J Cell Sci 2007 120 1393 1404 10.1242/jcs.000018 17374643 (Pubitemid 46780032)
3. Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). Duncan RE, Sarkadi-Nagy E, Jaworski K, Ahmadian M, Sul HS, J Biol Chem 2008 283 25428 25436 10.1074/jbc.M804146200 18614531
4. Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells. Huang SL, Shyu RY, Yeh MY, Jiang SY, Mol Cell Endocrinol 2000 159 15 24 10.1016/S0303-7207(99)00207-5 10687848 (Pubitemid 30067636)
5. Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes. Uyama T, Jin XH, Tsuboi K, Tonai T, Ueda N, Biochim Biophys Acta 2009 1791 1114 1124 10.1016/j.bbalip.2009.07.001 19615464
6. Cloning and functional characterization of the HRASLS2 gene. Shyu RY, Hsieh YC, Tsai FM, Wu CC, Jiang SY, Amino Acids 2008 35 129 137 10.1007/s00726-007-0612-2 18163183
7. cDNA cloning and characterization of human and mouse Ca(2+)-independent phosphatidylethanolamine N-acyltransferases. Jin XH, Uyama T, Wang J, Okamoto Y, Tonai T, Ueda N, Biochim Biophys Acta 2009 1791 32 38 10.1016/j.bbalip.2008.09. 006 19000777
8. Molecular cloning and biological activity of a novel Ha-Ras suppressor gene predominantly expressed in skeletal muscle, heart, brain, and bone marrow by differential display using clonal mouse EC cells, ATDC5. Akiyama H, Hiraki Y, Noda M, Shigeno C, Ito H, Nakamura T, J Biol Chem 1999 274 32192 32197 10.1074/jbc.274.45.32192 10542256 (Pubitemid 29522960)
9. Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Anantharaman V, Aravind L, Genome Biol 2003 4 11 10.1186/gb-2003-4-2-r11 12620121
10. The 2A proteins of three diverse picornaviruses are related to each other and to the H-rev107 family of proteins involved in the control of cell proliferation. Hughes PJ, Stanway G, J Gen Virol 2000 81 201 207 10640559 (Pubitemid 30047923)
11. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Tsai FM, Shyu RY, Jiang SY, Cell Signal 2006 18 349 358 10.1016/j.cellsig.2005.05.005 16005186 (Pubitemid 41661350)
12. Induction of apoptosis by the retinoid inducible growth regulator RIG1 depends on the NC motif in HtTA cervical cancer cells. Tsai FM, Shyu RY, Lin SC, Wu CC, Jiang SY, BMC Cell Biol 2009 10 15 10.1186/1471-2121-10-15 19245694
13. A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. Sturniolo MT, Dashti SR, Deucher A, Rorke AM, Broome RA, Chandraratna T, Keepers RL, Eckert RL, J Biol Chem 2003 278 48066 48073 10.1074/jbc.M307215200 12928434 (Pubitemid 37523257)
14. The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. Deucher A, Nagpal S, Chandraratna RA, Sepio DD, Robinson NA, Dashti SR, Eckert RL, Int J Oncol 2000 17 1195 1203 11078805
15. RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma. Shyu RY, Jiang SY, Chou JM, Shih YL, Lee MS, Yu JC, Chao PC, Hsu YJ, Jao SW, Br J Cancer 2003 89 146 151 10.1038/sj.bjc.6601049 12838316 (Pubitemid 36897950)
16. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, DiMao D, Hazarika P, Jackson B, Breuer-McHam J, Young J, Clayman G, Lippman SM, Chandraratna RA, Robinson NA, Deucher A, Eckert RL, Nagpal S, Clin Cancer Res 2000 6 3249 3259 10955811 (Pubitemid 30637755)
17. hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors. Siegrist S, Feral C, Chami M, Solhonne B, Mattei MG, Rajpert-De Meyts E, Guellaen G, Bulle F, Oncogene 2001 20 5155 5163 10.1038/sj.onc.1204658 11526504 (Pubitemid 32844044)
18. Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms. Lotz K, Kellner T, Heitmann M, Nazarenko I, Noske A, Malek A, Gontarewicz A, Schafer R, Sers C, Int J Cancer 2005 116 894 902 10.1002/ijc.21127 15856468 (Pubitemid 41209195)
19. Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Hajnal A, Klemenz R, Schafer R, Oncogene 1994 9 479 490 8290259 (Pubitemid 24041527)
20. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R, J Cell Biol 1997 136 935 944 10.1083/jcb.136.4.935 9049257 (Pubitemid 27098748)
21. The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Huang SL, Shyu RY, Yeh MY, Jiang SY, Anticancer Res 2002 22 799 804 12014653
22. TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells. Scharadin TM, Jiang H, Jans R, Rorke EA, Eckert RL, PLoS One 2011 6 23230 10.1371/journal.pone.0023230 21858038
23. A novel transglutaminase activator forms a complex with type 1 transglutaminase. Sturniolo MT, Chandraratna RA, Eckert RL, Oncogene 2005 24 2963 2972 10.1038/sj.onc.1208392 15846304 (Pubitemid 40675527)
24. RIG1 suppresses Ras activation and induces cellular apoptosis at the Golgi apparatus. Tsai FM, Shyu RY, Jiang SY, Cell Signal 2007 19 989 999 10.1016/j.cellsig.2006.11.005 17196792 (Pubitemid 46436438)
25. Sexually dimorphic development of mouse primordial germ cells: switching from oogenesis to spermatogenesis. Adams IR, McLaren A, Development 2002 129 1155 1164 11874911 (Pubitemid 34874138)
26. Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. Malki S, Nef S, Notarnicola C, Thevenet L, Gasca S, Mejean C, Berta P, Poulat F, Boizet-Bonhoure B, EMBO J 2005 24 1798 1809 10.1038/sj.emboj.7600660 15889150 (Pubitemid 40769499)
27. SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development. Wilhelm D, Hiramatsu R, Mizusaki H, Widjaja L, Combes AN, Kanai Y, Koopman P, J Biol Chem 2007 282 10553 10560 10.1074/jbc.M609578200 17277314 (Pubitemid 47093441)
28. Stage and region-specific localization of lipocalin-type prostaglandin D synthase in the adult murine testis and epididymis. Gerena RL, Eguchi N, Urade Y, Killian GJ, J Androl 2000 21 848 854 11105911
29. Conserved regulatory modules in the Sox9 testis-specific enhancer predict roles for SOX, TCF/LEF, Forkhead, DMRT, and GATA proteins in vertebrate sex determination. Bagheri-Fam S, Sinclair AH, Koopman P, Harley VR, Int J Biochem Cell Biol 2010 42 472 477 10.1016/j.biocel.2009.07.001 19616114
30. Sox9 in testis determination. Kobayashi A, Chang H, Chaboissier MC, Schedl A, Behringer RR, Ann N Y Acad Sci 2005 1061 9 17 10.1196/annals.1336.003 16467253 (Pubitemid 43211582)
31. SOX9 directly binds CREB as a novel synergism with the PKA pathway in BMP-2-induced osteochondrogenic differentiation. Zhao L, Li G, Zhou GQ, J Bone Miner Res 2009 24 826 836 10.1359/jbmr.081236 19113914
32. Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells. Malki S, Bibeau F, Notarnicola C, Roques S, Berta P, Poulat F, Boizet-Bonhoure B, Cancer Lett 2007 255 182 193 10.1016/j.canlet.2007.04.007 17532558 (Pubitemid 47268638)
33. Elevated expression of SOX9 is related with the progression of gastric carcinoma. Zhou CJ, Guo JQ, Zhu KX, Zhang QH, Pan CR, Xu WH, Wang HJ, Liu B, Diagn Cytopathol 2011 39 105 109 10.1002/dc.21348 20301211
34. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Ling S, Chang X, Schultz L, Lee TK, Chaux A, Marchionni L, Netto GJ, Sidransky D, Berman DM, Cancer Res 2011 71 3812 3821 10.1158/0008-5472.CAN-10-3072 21512138
35. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, Li H, Zhao J, Diagn Pathol 2012 7 44 10.1186/1746-1596-7-44 22515642
36. Involvement of the prostaglandin D2 signal pathway in retinoid-inducible gene 1 (RIG1)-mediated suppression of cell invasion in testis cancer cells. Wu CC, Shyu RY, Wang CH, Tsai TC, Wang LK, Chen ML, Jiang SY, Tsai FM, Biochim Biophys Acta 2012 1823 2227 2236 10.1016/j.bbamcr.2012.08.013 22960220
37. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. Lee JM, Dedhar S, Kalluri R, Thompson EW, J Cell Biol 2006 172 973 981 10.1083/jcb.200601018 16567498
38. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, Gespach C, Bracke M, Berx G, Histochem Cell Biol 2008 130 481 494 10.1007/s00418-008-0464-1 18648847
39. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. Angeli V, Faveeuw C, Roye O, Fontaine J, Teissier E, Capron A, Wolowczuk I, Capron M, Trottein F, J Exp Med 2001 193 1135 1147 10.1084/jem.193.10.1135 11369785 (Pubitemid 32488366)
40. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN, J Immunol 2003 171 3936 3940 14530310 (Pubitemid 37238665)
41. PGD synthase and PGD2 in immune resposne. Joo M, Sadikot RT, Mediators Inflamm 2012 2012 503128 22791937
42. A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils. Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, Beri R, Sargent C, Schmidt JA, Lang-Loidolt D, Eur J Clin Invest 2008 38 663 671 10.1111/j.1365-2362.2008.01989.x 18837743
43. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Nithipatikom K, Isbell MA, Lindholm PF, Kajdacsy-Balla A, Kaul S, Campell WB, Clin Exp Metastasis 2002 19 593 601 10.1023/A:1020915914376 12498388 (Pubitemid 35454569)
44. Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer. Yoshida T, Ohki S, Kanazawa M, Mizunuma H, Kikuchi Y, Satoh H, Andoh Y, Tsuchiya A, Abe R, Surg Today 1998 28 740 745 10.1007/BF02484622 9697269 (Pubitemid 28341300)
45. Prostaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells. Zhang A, Dong Z, Yang T, Am J Physiol Renal Physiol 2006 291 1332 F1342 10.1152/ajprenal.00131.2006 16896186 (Pubitemid 44887247)
46. TIG3 interaction at the centrosome alters microtubule distribution and centrosome function. Scharadin TM, Jiang H, Martin S, Eckert RL, J Cell Sci 2012 125 2604 2614 10.1242/jcs.096495 22427689
47. Regulation of peroxisomal lipid metabolism by catalytic activity of tumor suppressor H-rev107. Uyama T, Ichi I, Kono N, Inoue A, Tsuboi K, Jin XH, Araki N, Aoki J, Arai H, Ueda N, J Biol Chem 2012 287 2706 2718 10.1074/jbc.M111. 267575 22134920
48. H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling. Nazarenko I, Kristiansen G, Fonfara S, Guenther R, Gieseler C, Kemmner W, Schafer R, Petersen I, Sers C, Am J Pathol 2006 169 1427 1439 10.2353/ajpath.2006.051341 17003497 (Pubitemid 351194375)
49. Evidence that sequence homologous region in LRAT-like proteins possesses anti-proliferative activity and DNA binding properties: translational implications and mechanism of action. Simmons DP, Peach ML, Friedman JR, Green MM, Nicklaus MC, De Luca LM, Carcinogenesis 2006 27 693 707 16234259
50. Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Ou CC, Hsu SC, Hsieh YH, Tsou WL, Chuang TC, Liu JY, Kao MC, Carcinogenesis 2008 29 299 306 18174256